Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

December 22, 2022

https://www.globenewswire.com/news-release/2022/12/22/2578490/0/en/Unicycive-Issued-Notice-of-Acceptance-to-Initiate-Phase-1-Study-of-UNI-494-Following-Review-of-Clinical-Trial-Application-by-the-Medicines-and-Healthcare-Products-Regulatory-Agency.html

LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for UNI-494 first-in-human Phase 1 study in healthy volunteers.

Read more at globenewswire.com

Related news for (UNCY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.